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Introduction
Pancreatic neuroendocrine tumors (PNETs) are rare malignant neoplasms 
which incidence is continually increasing. They are characterized by diverse 
biological behaviour and impact on the patients’ prognosis, ranging from 
clinicaly indolent to very aggressive. Oxytocin receptor (OXTR) is a mem-
ber of the family of G-protein receptors and is present on the cell-surface 
of the gastrointestinal organs. Unfortunately, theimpact of OXTR signaling 
on the development of PNETs and its underlying molecular mechanisms 
involved in gastrointestinal oncogenesis remains unsufficiently researched. 
Theaim of our study was to assess the expression of OXTR in a group of 
patients diagnosed with metastatic PNETs.
Material and methods
Metatatic PNETs (liver metastases) specimens (n = 24) matched control 
(normal) tissue were surgically collected and mRNA expression was de-
termined by Real-time polymerase chain reaction (Real-time-PCR). OXTR 
expression for tumor and control tissue was additionally analysed by immu-
nohistochemistry.
Results
Compared to normal tissue, the OTXR showed significant overexpression in 
metastatic PNETs. Moreover, significant overexpression of OXTR in tumor 
tissue was confirmed by immunohistochemistry.
Conclusion
Our findings highlight the possibility of making OXTR a promising novel 
molecular target for imaging and different therapeutic approach in patients 
diagnosed with metastatic PNETs.
DOI: 10.1530/endoabs.70.AEP731
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Background
Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms 
and it is malignant in only 10% of cases. Locoregional invasion or metas-
tases define malignancy, whereas dimension (> 2 cm), CK19 status, tumor 
staging and grading (Ki67 > 2%), and age of onset (> 50 years) can be con-
sidered elements of suspect.
Case presentation
We report a case of malignant insulinoma in a 80 year old woman present-
ing symptoms compatible with hypoglycemia. Low blood glucose levels 
(< 40 mg/dl) were documented during of these episodes. Symptoms re-
gressed with food intake and intravenous glucose administration. No abnor-
mality was detected in the biochemical evaluation. Prolong fasting test was 
performed, and the patient underwent symptomatic hypoglycemia at the 5th 
hour. Plasma glucose level was 39  mg/dl, insulin level 36.4  uIU/mL and 
C-peptide 9.28 ng/ml. Glucagon responce was measured 10   min. intervals, 
85 mg/dl, 95 mg/dl and 113 mg/dl respectively. These results were sugges-
tive of endogenous hyperinsulinemia. Magnetic resonance imaging revealed 
a invasive mass in the pancreatic tail location ∼ 63 × 40 mm in size and mul-
tiple metastatic nodules in the the liver. Ga–68 DOTATATE PET-CT, which 
showed a lesion located in the pancreatic tail location and multıpl metastatic 
lesion in the liver, with a high somatostatin receptor density. Tru-cut bi-
opsy made from liver lesions revealed the insulinoma tumour metastasis. 
Synaptophysin, pancytoceratine and chromogranin were positive. The histo-
pathological diagnosis was suggestive of a neuroendocrine, grade-2 tumour 
(mitotic rate 1/10 HPF, KI-67 proliferative index 15%). Lanreotide 120 mg 
IM was started an every 28 days basis. The patient received 2 infusions of 
radiolabeled somatostatin analog lutetium (177LU) 8 weeks apart and de-
nied any hypoglycemia. After the second administration of the lutetium, 
Ga–68 DOTATATE PET-CT had shown objective metabolic and radiologic 
response to treatment. Lutetium treatment was given as 8 cycles. Treatment 
of the patient with metabolic and radiological responses continues with lan-
reotide 90 mg/every 28 days.
Conclusions
We report a case of metastatic insulinoma treatment with somatostatin an-
alog and Lutetium. Due to previous glycemic control reports and objective 
responses in unresectable cases, we decided to use Lutetium together with 
lanreotide. The patient’s hypoglycaemia improved immediately after treat-
ment. Unresectable metastatic insulinomas may present as a major thera-
peutic challenge for the physician. Treatment with landreotide and Lutetium 
Therefore, we conclude thatEMT occurs in some somatotropinomas, but it 
does not seem to explain their response to SRL in this subset of tumors. 
However, in the rest of somatotropinoma SNAI1 and RORC may predict the 
response to SRL treatment.
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Background
The altered DNA methylation of certain genes in Pituitary Neuroendocrine 
Tumors (PitNETs) are well known. However little information is available 
regarding global methylation changes and the process of demethylation in 
these tumors. In addition, influencing global methylation-demethylation 
could be a potential new therapeutic option especially in clinically non-func-
tional PitNETs.
Material and methods
Overall, 44 fresh frozen pituitary adenoma tissues (29 gonadotroph, 12 so-
matotroph, 3 corticotroph) were collected and characterized according to 
the 2017 WHO classification. Decitabine was used to alter global methyla-
tion-demethylation status on in vitro GH3 and RC-4B/B cell lines. In tissue 
samples 5-hydroxymethylcytisone (5 hmC), UHRF1-2 protein and Ki-67 
were assessed by immunohistochemistry; gene expression of DNA Meth-
yl-transferase (DNMT1), methyl-cytosine dioxygenases (TET1-3) and ubiq-
uitin-like with PHD and ring finger domain (UHRF1-2) were investigated 
by RT-qPCR. 5-methylcytosine (5 mC) and 5 hmC level were determined by 
HPLC-MS/MS method.
Results
Decitabine decreased 5-methylcytosine (5 mC) and increased 5 hmC levels 
in vitro in both pituitary cell lines. Parallel, cell proliferation and viability 
were decreased significantly. UHRF1-2 were also altered upon decitabine 
treatment in vitro. Interestingly, in PitNET tissue samples 5 hmC was grad-
ually decreased in samples with higher Ki-67 index. In samples with differ-
ent histology UHRF2 showed different expression, while UHRF1 showed 
gradual increase in adenoma samples with higher Ki-67 index. Additionally, 
UHRF2 positively correlated with 5 hmC level in pitNET tissues and both 
UHRF1 and UHRF2 showed significant positive correlation with DNMT1 
and TET1-3 expression.
Conclusion
Our results showed that methylation-demethylation process (5 hmC, 
DNMT1, TET1-3 and UHRF1-2) is closely linked to proliferative behaviour 
of PitNETs. Altering global 5 mC and 5 hmC level can be a potential, new 
therapeutic target in therapy resistant pituitary tumors.
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